KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Castle Biosciences (CSTL) EBITDA (2018 - 2025)

Castle Biosciences (CSTL) has disclosed EBITDA for 8 consecutive years, with -$3.8 million as the latest value for Q4 2025.

  • Quarterly EBITDA fell 194.49% to -$3.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$42.8 million through Dec 2025, down 593.77% year-over-year, with the annual reading at -$42.8 million for FY2025, 593.77% down from the prior year.
  • EBITDA hit -$3.8 million in Q4 2025 for Castle Biosciences, up from -$6.8 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $5.1 million in Q3 2024 to a low of -$31.5 million in Q1 2023.
  • Historically, EBITDA has averaged -$10.2 million across 5 years, with a median of -$6.6 million in 2021.
  • Biggest five-year swings in EBITDA: tumbled 1183.8% in 2023 and later surged 171.58% in 2024.
  • Year by year, EBITDA stood at -$6.4 million in 2021, then crashed by 255.09% to -$22.8 million in 2022, then skyrocketed by 75.22% to -$5.7 million in 2023, then skyrocketed by 171.58% to $4.0 million in 2024, then plummeted by 194.49% to -$3.8 million in 2025.
  • Business Quant data shows EBITDA for CSTL at -$3.8 million in Q4 2025, -$6.8 million in Q3 2025, and -$4.3 million in Q2 2025.